VECTAB

Serial Number 79352355
Registration 7349426
700

Registration Progress

Application Filed
Aug 1, 2022
Under Examination
Approved for Publication
Jan 23, 2024
Published for Opposition
Jan 23, 2024
Registered
Apr 9, 2024

Trademark Image

VECTAB

Basic Information

Serial Number
79352355
Registration Number
7349426
Filing Date
August 1, 2022
Registration Date
April 9, 2024
Published for Opposition
January 23, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Apr 9, 2024
Registration
Registered
Classes
005 042 044

Rights Holder

VectorY B.V.

99
Address
Science Park 408
NL-1098 XH AMSTERDAM
NL

Ownership History

VectorY B.V.

Original Applicant
99
NL

VectorY B.V.

Owner at Publication
99
NL

VectorY B.V.

Original Registrant
99
NL

Legal Representation

Attorney
Douglas T. Johnson

USPTO Deadlines

Next Deadline
1721 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-04-09)
Due Date
April 09, 2030
Grace Period Ends
October 09, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

33 events
Date Code Type Description Documents
Jan 17, 2025 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Jan 1, 2025 FIMP P FINAL DISPOSITION PROCESSED Loading...
Jan 1, 2025 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Oct 19, 2024 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Apr 9, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Apr 9, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Apr 1, 2024 OPNX P NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Loading...
Mar 13, 2024 OPNR P NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Loading...
Mar 13, 2024 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Jan 23, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 23, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 22, 2024 GPNX P NOTIFICATION PROCESSED BY IB Loading...
Jan 3, 2024 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Loading...
Jan 3, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 3, 2024 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Dec 18, 2023 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 12, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Dec 12, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Dec 12, 2023 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Dec 12, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Dec 8, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 7, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 7, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 22, 2023 RFNT P REFUSAL PROCESSED BY IB Loading...
Jun 27, 2023 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Jun 27, 2023 RFRR P REFUSAL PROCESSED BY MPU Loading...
May 20, 2023 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
May 19, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
May 18, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 11, 2023 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
Oct 18, 2022 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Oct 14, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 13, 2022 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Viral systems comprised of viral vectors combined with antibodies; gene therapy systems comprised of viral vectors combined with antibodies; nucleic acid delivery systems being therapeutic agents for delivery to human tissue namely viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for the treatment neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; clinical medical reagents for use in nucleic acid-based therapy, cell therapy, pharmaceutical preparations, prophylaxis products preparations and other pharmaceutical products preparations and other pharmaceutical products preparations for use in nucleic acid-based therapy, gene therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases
Class 042
Scientific and medical research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; Scientific and medical research and product development in the field of pharmaceutics
Class 044
Medical treatment by gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; consultancy in the field of pharmaceutics

Classification

International Classes
005 042 044